{"id":666579,"date":"2023-09-06T20:16:01","date_gmt":"2023-09-06T20:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666579"},"modified":"2023-09-06T20:16:01","modified_gmt":"2023-09-06T20:16:01","slug":"delveinsight-highlights-major-advances-transformative-therapies-and-30-leading-players-wheeling-the-alkpositive-nonsmall-cell-lung-cancer-clinical-trial-pipeline-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/delveinsight-highlights-major-advances-transformative-therapies-and-30-leading-players-wheeling-the-alkpositive-nonsmall-cell-lung-cancer-clinical-trial-pipeline-landscape_666579.html","title":{"rendered":"DelveInsight Highlights Major Advances, Transformative Therapies, and 30+ Leading Players Wheeling the ALK-positive Non-Small Cell Lung Cancer Clinical Trial Pipeline Landscape"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1694002045.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"DelveInsight Highlights Major Advances, Transformative Therapies, and 30+ Leading Players Wheeling the ALK-positive Non-Small Cell Lung Cancer Clinical Trial Pipeline Landscape\" src=\"https:\/\/www.abnewswire.com\/uploads\/1694002045.png\" alt=\"DelveInsight Highlights Major Advances, Transformative Therapies, and 30+ Leading Players Wheeling the ALK-positive Non-Small Cell Lung Cancer Clinical Trial Pipeline Landscape\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">The ALK-positive Non-Small Cell Lung Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of ALK-positive Non-Small Cell Lung Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the ALK-positive Non-Small Cell Lung Cancer pipeline landscape and fostering the potential growth of ALK-positive Non-Small Cell Lung Cancer therapeutic advancements.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment.<\/li>\n<li>The leading companies working in the ALK-positive Non-Small Cell Lung Cancer Market include <strong><em>GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutical, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso<\/em><\/strong>, and others.<\/li>\n<li>Promising ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include <strong><em>Alkotinib Capsules, Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, X-396 capsule<\/em><\/strong>, and others.<\/li>\n<li>On June 2023, Pfizer announced a study of Phase 1 &amp; 2 Clinical Trials for PF-06463922 and Crizotinib. Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non-small cell lung cancer patients.<\/li>\n<li>On August 2023, Betta Pharmaceuticals Co. Ltd announced a study of Phase 2 Clinical Trials for X-396 capsule. The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib. While exploring the relationship between biomarkers and drug efficacy and safety.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The ALK-positive Non-Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage ALK-positive Non-Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the ALK-positive Non-Small Cell Lung Cancer clinical trial landscape.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it&#8217;s a gene rearrangement&mdash;a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about ALK-positive Non-Small Cell Lung Cancer Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for ALK-positive Non-Small Cell Lung Cancer Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ensartinib: Betta Pharmaceuticals\/Xcovery<\/li>\n<li>TQ-B3139 &#8211; Chia Tai Tianqing Pharmaceutical Group<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The ALK-positive Non-Small Cell Lung Cancer companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals\/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutical, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies- Alkotinib Capsules, Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, X-396 capsule, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for ALK-positive Non-Small Cell Lung Cancer Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Collaboration Deals<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Ensartinib: Betta Pharmaceuticals\/Xcovery<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Bintrafusp alfa: EMD Serono\/GlaxoSmithKline\/Merck<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>PLB1003: Beijing Pearl Biotechnology Limited Liability Company<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Pre-clinical and Discovery Stage Products<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Key Products<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer- Unmet Needs<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Analyst Views<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the ALK-positive Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=delveinsight-highlights-major-advances-transformative-therapies-and-30-leading-players-wheeling-the-alkpositive-nonsmall-cell-lung-cancer-clinical-trial-pipeline-landscape\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=delveinsight-highlights-major-advances-transformative-therapies-and-30-leading-players-wheeling-the-alkpositive-nonsmall-cell-lung-cancer-clinical-trial-pipeline-landscape\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The ALK-positive Non-Small Cell Lung Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of ALK-positive Non-Small Cell Lung Cancer treatments, including those already in the market, as well as those in different phases of clinical development. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/delveinsight-highlights-major-advances-transformative-therapies-and-30-leading-players-wheeling-the-alkpositive-nonsmall-cell-lung-cancer-clinical-trial-pipeline-landscape_666579.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-666579","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=666579"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666579\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=666579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=666579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=666579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}